**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 65-year-old man developed haemolysis, that lead to acute renal failure during off-label treatment with hydroxychloroquine for COVID-19.

The man was admitted to the hospital for hypoxia in mid-march 2020. His medical history was significant for hypertension and type 2 diabetes. He was found to be positive for COVID-19. From the day of admission, he started receiving off-label therapy with hydroxychloroquine 400mg BID on day 1, followed by 200mg BID on day 2−5, along with off-label azithromycin 500mg on day 1, followed by 250mg on day 2−5 \[*routes not stated*\]. On the next day of admission, Hb level was found to be dropped to 11.8 g/dL and on the following day, his condition got worsened. He was then shifted to the ICU. Investigations on day 5 revealed that the haptoglobin was below detection level, indicating severe haemolysis.

The man\'s therapy with hydroxychloroquine was discontinued on day 5 of its initiation. It was later revealed that he had glucose-6-phosphate-dehydrogenase (G6PD) deficiency (G6PD was found to be below 0.2 U/g of Hb). He developed acute respiratory distress syndrome due to COVID-19, for which he required intubation for 7 days. He underwent continuous veno-venous haemodialysis and filtration during the ICU stay. The Hb further dropped to 7.2 g/dL. He received multiple blood transfusions. The haptoglobin again became detectable on day 15 after initiation of hydroxychloroquine. The acute haemolysis was considered to be due to use of hydroxychloroquine and the underlying G6PD deficiency, that further lead to acute renal failure. After 18 days of the ICU stay, he was transferred to the conventional unit.
